Abstract
Background
Transfusion associated Hepatitis B virus (TAHBV) continues to be a major problem despite mandatory screening for Hepatitis B surface Antigen (HBsAg). Presence of HBsAg is the common method for detecting hepatitis B infection. Unfortunately, this marker is not detected during the window period of the infection. Nigeria being a developing country cannot afford DNA testing of all collected units of blood which serve as the only possibility of achieving zero risk of transfusion associated HBV. Five different serological makers of hepatitis B virus (HBV) infection were therefore assessed to evaluate the reliability of using HBsAg marker alone in diagnosis of HBV infection among blood donors and to detect the serological evidence of the infection at the window period. This will preclude the possibility of transmitting hepatitis B through transfusion of Hepatitis B surface antigen (HBsAg) negative blood in Nigeria.
Methods
Between July and August 2009, 92 blood donors were enrolled for the study. The prevalence of 5 different markers of Hepatitis B virus infection was detected using Enzyme Linked Immunosorbent Assay (ELISA). Demographic factors were assessed during the study.
Results
HBsAg and its antibody (anti-HBs) was detected in 18 (19.6%) and 14(15.2%) of the 92 blood donors respectively. Anti-HBc IgM was found in 12(13.0%) of the 92 blood donors while Hepatitis B envelope antigen (HBeAg) and its antibody (anti-HBe) were detected in 4(8.9%) and 12(26.7%) respectively from 45 donors sampled. HBeAg is a marker of high infectivity and appears after HBsAg. At least one serological marker was detected in 30(32.6%) of the blood donors. Five (5.4%) of the 92 donors had anti-HBc IgM as the only serological evidence of hepatitis B virus infection.
Conclusions
The result of this study shows that five donors have anti-HBcIgM as the only serological evidence of HBV infection. Inclusion of anti-HBcIgM in routine screening of blood donors in Nigeria should be encouraged. This is the first study to assess anti-HBcIgM in the country.
Keywords: Hepatitis B, Transfusion, Serological markers, ELISA, Blood donors
Background
Hepatitis B virus (HBV) infection with its associated sequel is a disease of major public health importance, being the 10th leading cause of death globally [1,2]. HBV infection accounts for 500,000 to 1.2 million deaths each year [3]. Of the approximately 2 billion people infected worldwide, more than 350 million are chronic carriers of HBV [4]. Approximately 15-40% of infected patients will develop cirrhosis, liver failure or hepatocellular carcinoma (HCC) [5,6]
The aetiological agent (Hepatitis B virus) is a member of the family Hepadnaviridae and the genus Orthohepadnavirus [7]. It is a double stranded circular DNA virus composed of an outer envelope containing hepatitis B surface antigen (HBsAg) and an inner nucleocapsid consisting of hepatitis B envelope antigen (HBeAg) and hepatitis B core antigen (HBcAg). Corresponding antibodies to each of these antigens are Hepatitis B surface antibody (anti-HBs or HBsAb), Hepatitis B envelope antibody (anti-HBe or HBeAb) and hepatitis B core IgM and IgG antibody (anti-HBc or HBcAb) [8]. The viral core also contains double stranded DNA genome and DNA polymerase. The serological markers of Hepatitis B virus are HBsAg, anti-HBs, HBcAg, anti-HBc (IgM and IgG), HBeAg, anti-HBe, and HBV DNA; these are important as they can be used in the diagnosis of the infection and to determine the severity of the infection [9].
Following infection by the hepatitis B virus (HBV), the first serological marker to appear in the blood is the HBV DNA, followed by HBsAg, the DNA polymerase and HBeAg. Thereafter, the antibodies to the hepatitis B antigens (HBcAb, HBeAb and HBsAb) can be detected. Screening of donated blood by enzyme-linked immunosorbent assay (ELISA) for HBsAg is the common method for detecting hepatitis B infection [10]. Screening of blood for the detection of this viral marker, however, does not rule out the risk of transmission of hepatitis B totally, because during the host serological response to infection, there is a phase during which the HBsAg cannot be detected in the blood although hepatitis B infection is present. This phase is known as the 'window period'. It represents a carrier state of the disease.
Findings indicate that testing done for HBsAg alone is not sufficient to eliminate HBV infection from blood supply [10-13]. A marker which would be indicative of hepatitis B infection during the window period is thus of paramount importance in blood banking especially in low income country like Nigeria, where DNA testing of all collected units of blood is not feasible.
This study was therefore designed to evaluate the reliability of using HBsAg marker alone, in diagnosis of HBV infection among blood donors and to detect the presence of a marker which would be indicative of hepatitis B infection during the window period.
Results and Discussion
Results
Prevalence of HBV Marker
Of the 92 blood samples tested, HBsAg was detected in 18 (19.6%), anti-HBs in 14(15.2%) and anti-HBcIgM in 12(13.0%). HBeAg and anti-HBe were detected in 4(8.9%) and 12(26.7%) respectively from 45 donors sampled. Table 1 summarises the frequency of the 5 markers of HBV tested among the blood donors. At least one serological marker was detected in 30(32.6%) of the blood donors (Table 2). Five (5.4%) of the donors had anti-HBcIgM as the only serological evidence of hepatitis B virus infection.
Table 1.
Prevalence of Hepatitis B Virus Serological markers among blood donors
| SEROLOGICAL MARKERS | NUMBER OF SAMPLES | POSITIVE (%) |
|---|---|---|
| HBsAg | 92 | 18(19.6) |
| HBsAb | 92 | 14(15.2) |
| HBeAg | 45 | 4(8.9) |
| HBeAb | 45 | 12(26.7) |
| HBcIgM | 92 | 12(13.0) |
Table 2.
Donors showing detectable evidence of HBV infection by presence of at least one serological marker
| S/N | Sample code | Age | Sex | SEROLOGICAL MARKERS | ||||
|---|---|---|---|---|---|---|---|---|
| HBsAg | HBsAb | HBcIgM | HBeAg | HBeAb | ||||
| 1 | 111 | 30 | M | ✓ | ✓ | ✓ | ||
| 2 | 117 | 23 | M | ✓ | ✓ | |||
| 3 | 137 | 19 | M | ✓ | ✓ | |||
| 4 | 138 | 41 | M | ✓ | ✓ | |||
| 5 | 79 | 45 | M | ✓ | ✓ | ✓ | ||
| 6 | 80 | 37 | M | ✓ | ✓ | ✓ | ||
| 7 | 112 | 29 | M | ✓ | ✓ | ✓ | ||
| 8 | 113 | 22 | M | ✓ | ✓ | |||
| 9 | 121 | 22 | M | ✓ | ✓ | |||
| 10 | 124 | 35 | M | ✓ | ✓ | |||
| 11 | 153 | 19 | M | ✓ | ✓ | |||
| 12 | 154 | 21 | M | ✓ | ✓ | ✓ | ||
| 13 | 155 | 20 | M | ✓ | ✓ | |||
| 14 | 157 | 28 | M | ✓ | ✓ | ✓ | ||
| 15 | 158 | 32 | M | ✓ | ✓ | ✓ | ||
| 16 | 116 | 23 | M | ✓ | ✓ | ✓ | ||
| 17 | 123 | 27 | M | ✓ | ||||
| 18 | 163 | 33 | M | ✓ | ✓ | |||
| 19 | 165 | 23 | M | ✓ | ||||
| 20 | 189 | 22 | M | ✓ | ||||
| 21 | 203 | 26 | M | ✓ | ✓ | |||
| 22 | 15-5 | 29 | M | ✓ | ||||
| 23 | 04 | 21 | M | ✓ | ||||
| 24 | 07 | 27 | F | ✓ | ||||
| 25 | 08 | 36 | M | ✓ | ✓ | |||
| 26 | 210 | 23 | M | ✓ | ✓ | |||
| 27 | 215 | 19 | F | ✓ | ||||
| 28 | 69 | 20 | F | ✓ | ✓ | |||
| 29 | 190 | 21 | M | ✓ | ||||
| 30 | 124 | 28 | M | ✓ | ✓ | |||
| TOTAL | 18 | 14 | 12 | 4 | 12 | |||
Sex and Age distribution of donors with HBV marker
Of the 69 male blood donors enrolled for this study, 15 (21.7%) 13(18.8%) and12 (17.4%) were positive for HBsAg, HBsAb and Anti-HBcIgM respectively while 4(8.9%) and 12 (26.7%) were positive for HBeAg and HBeAb respectively among the 45 donors tested. Among the 23 females enrolled in the study no positivity was recorded for HBcAb, HBeAg and its Ab, however, 3(13%) and 1(4.3%) were positive for HBsAg and Ab respectively. (Table 3). There is no significant difference (P < 0.005) between the sex distribution of HBV markers among blood donors. The age distribution of blood donors with serological marker is shown in table 4.
Table 3.
Sex distribution of blood donors with HBV markers
| Number Tested (%) | Positive (%) | Positive (%) | |||||
|---|---|---|---|---|---|---|---|
| HBsAg | HBsAb | Anti-HBcIgM | No tested for HBeAg &Ab | HBeAg | HBeAb | ||
| Male | 69(75%) | 15 (21.7) | 13 (18.8) | 12 (17.4) | 45 | 4 (8.9) | 12(26.7) |
| Female | 23(25%) | 3 (13.0) | 1 (4.3) | 0 (0) | 45 | 0 (0) | 0 (0) |
| Total | 92 | 18 | 14 | 12 | 45 | 4 | 12 |
Table 4.
Age distribution of blood donors with Hepatitis B Virus serological markers
| Positive (%) | Positive (%) | ||||||
|---|---|---|---|---|---|---|---|
| Age | No tested | HBsAg | HBsAb | HBcIgM | No tested | HBeAg | HBeAb |
| 18-23 | 49 | 8(16.3) | 6(12.2) | 4(8.2) | 19 | 2(10.5) | 6(31.6) |
| 24-29 | 18 | 5(27.8) | 2(11.1) | 4(22.2) | 6 | 0(0) | 2(33.3) |
| 30-35 | 13 | 1(7.7) | 3(23.1) | 3(23.1) | 10 | 0(0) | 2(20.0) |
| 36-41 | 10 | 3(30.0) | 2(20.0) | 1(10.0) | 8 | 1(12.5) | 1(12.5) |
| 42-47 | 2 | 1(50.0) | 1(50.0) | 0(0) | 2 | 0(0) | 1(50.0) |
| TOTAL | 92 | 18(19.6) | 14(15.2) | 12(13.0) | 45 | 4(8.9) | 12(26.7) |
Discussion
Transfusion of blood collected from a donor who is in the window period may lead to post transfusion hepatitis B in the recipient [14,15]. The result of this study showed that 5 donors (5.4%) had anti-HBcIgM antibody as the only serologic evidence of HBV. They have not seroconverted to anti-HBs, hence might be infectious. Previous studies have demonstrated the presence of HBV DNA in anti-HBc-only donors [16,17]. These findings corroborate earlier report that testing blood donors for HBsAg alone is not sufficient to eliminate HBV from blood supply [11]
Chaudhuri et al., 2003 observe the presence of HBV DNA in one-fifth of anti-HBc-only donors studied and stated that, reactivity to anti-HBc only can predict cryptic HBV infection. A report from Japan [16] demonstrated the presence of HBV DNA in 38 percent of HBsAg-negative anti-HBc-reactive donors. The only serologic evidence of infection with hepatitis B in 5 of the 92 blood donors in this study is the presence of IgM antibody to the core antigen (HBcIgM). Blood from the 5 anti-HBc IgM only donors from this study might have been transfused to innocent patients (since the donors were screened negative due to no detectable HBsAg in their blood), thereby increasing the number of possible post transfusion HBV.
It had been observed earlier [10,14,15] that the screening test for detection of HBsAg does not rule out the transmissions of Hepatitis B as the donor might be in the "window period" and detection of the antibody to the hepatitis B core antigen HBcIgM type serves as a useful serological marker during this period. A prevalence of 5.4% observed for anti-HBc in this study is higher compared with 0.39% observed by Col et al., [10]. This might be indicating a progressive increase in the possibility of transfusing HBV through blood donation.
Anti-HBc has been found to be an excellent indicator of occult HBV infection during the window period [18,19,15]. Other markers for detecting occult HBV infection in an HBsAg negative blood donor such as detection of HBV DNA by polymerase chain rection (PCR) may not be cost effective [20]). Detection of anti-HBc has contributed significantly in reducing the incidence of post transfusion hepatitis B amongst patients [21-23]. The IgM class of the anti-HBc is a marker that indicates recent infection. The IgG variety of anti-HBc appears later during the infection and points to a past HBV infection. Individuals with IgG variety of anti-HBc may not be infectious as they may have sufficiently high titres of antibodies to HBsAg (anti-HBs), which are protective in nature and the affected individuals may actually be disease free. The sero-prevalence rate of anti-HBcIgM in the general population in Nigeria is not available. To the best of our knowledge, the only published data on estimation of anti-HBc in Nigeria was on the prevalence of anti-HBc total (i.e. both IgG and IgM) amongst patients with chronic liver disease and it was estimated as 90% [24]. Anti-HBcIgG may remain positive for life in an infected individual although the individual has protective levels of anti-HBs and therefore does not necessarily mean that blood of such a donor is infectious. Consequently, anti-HBcIgM is considered to be a more specific marker for HBV infection during the window period [25-27].
Conclusion
The result of this study shows the need to include anti-HBcIgM in routine screening of blood donors in Nigeria. It also confirms the fact that testing blood donors for HBsAg alone is not sufficient to eliminate HBV from blood supply. Although, the possibility of achieving zero risk of transfusion associated HBV infection depend largely on DNA testing of all the collected units of blood [13] before transfusion; however, since this is not done in many developing countries including Nigeria due to cost, this study recommends the inclusion of anti-HBcIgM in routine screening of blood donors in countries where DNA testing is not done. This will go a long way in reducing transfusion associated Hepatitis B Virus (TAHBV) infection.
Methods
Sample Collection and Preparation
Ninety-two (M = 69, F = 23; Age range: 18-50 years; Mean: 24.9 years) blood donors in Ile-Ife, Osun State were enrolled for the study between July and August 2009. Five millilitres of blood was collected from each donor by venepuncture into a labelled sterile container free of anticoagulants or preservative. Each blood specimen was separated by low centrifugation at 500 g for 5 minutes and the serum transferred into labelled cryovial. Thereafter, the sera were kept frozen at -20C until analysed.
Assay procedure
Five different markers of HBV infection (HBsAg, anti-HBs, anti-HBcIgM, HBeAg and anti-HBe) were detected by commercial Enzyme-linked immunosorbent assay (ELISA) kit (Diapro Diagnotic Bioprobes Milano- Italy). The kit, reagent and sera were brought to room temperature before starting the assay. The wells of each of the microplate were identified for controls and samples. For each of the assays, there were two negative controls and one positive control. One hundred microlitres each of negative control, positive control and sample were pipetted into the appropriate wells except for HBsAg where 50 μl was used as stated by the manufacturer. The plates were incubated at 37°C for 60 minutes, washed with wash buffer 5 times with soaking time of about 30 seconds in between each washing. A second incubation at same temperature and time was carried out after the addition of enzyme conjugate and the plates were washed as previously described. A final incubation at room temperature for 10 to 15 minutes depending on manufacturer's instruction for the specific serological marker was done after the addition of substrate (a chromogen). This made the positive samples turn to blue while the negatives were colourless. Addition of 100 μl of the stop solution (sulphuric acid) turned the positive samples from blue to yellow. The results were read using a 450 nm filter microplate reader.
Statistical analysis
The prevalence of serological markers was compared in terms of gender by use of chi-square tests.
List of Abbrevations
Anti-HBcIgM: Hepatitis B Core IgM Antibody; HBsAg: Hepatitis B surface Antigen; TAHBV: Transfusion Associated Hepatitis B Virus; HBV: Hepatitis B Virus; ELISA: Enzyme Linked Immunosorbent Assay; Anti-HBs or HBsAb: Hepatitis B surface Antibody; HBeAg: Hepatitis B envelope Antigen; Anti-HBe or HBeAb: Hepatitis B envelope antibody.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MOJ conceived the study. MOJ and OAA were in charge of recruitment of patients and collection of samples. MOJ, OAA and ED undertook laboratory analysis; MOJ analyzed the data and prepared the manuscript; OAA and MOA provided ideas and comments during manuscript preparation. All authors have read through and approved the final manuscript.
Contributor Information
Margaret Oluwatoyin Japhet, Email: megdeoti@yahoo.com.
Olufisayo Adeyemi Adesina, Email: adesinafat@yahoo.co.uk.
Emmanuel Donbraye, Email: jehoshua2001@yahoo.com.
Moses Olubusuyi Adewumi, Email: adewumi1@hotmail.com.
Acknowledgements
We thank the blood donors who participated in this research.
References
- Alao OO, Okwori OO, Egwu C, Audu F. Seroprevalence of Hepatitis B surface antigen among prospective Blood donor in an Urban Area of Benue state. The internet J of Hematology. 2009;5(2) [Google Scholar]
- Lavanchy D. Hepatits B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J viral Hepatol. 2004;11(2):97–107. doi: 10.1046/j.1365-2893.2003.00487.x. [DOI] [PubMed] [Google Scholar]
- Alavian Seyed-Moayed, Behnava Bita. What is the reason for poor outcome of Antepartum immunopoplylaxis of Heptatis B Immunoglobulin in prevention of vertical Hepatitis B Transmission? Heptatitis monthly. 2007;7(3):163–165. [Google Scholar]
- Schmidt M, Nubling CM, Scheiblanres H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK. Anti-HBC screening of blood donors: a comparison of nine anti-HBc test. Vox sang. 2006;91:237–243. doi: 10.1111/j.1423-0410.2006.00818.x. [DOI] [PubMed] [Google Scholar]
- Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683. doi: 10.1056/NEJM200205303462202. [DOI] [PubMed] [Google Scholar]
- Hicks Rob. Hepatitis B. 2009. http://www.bbc.co.uk/health/physical_health/conditions/hepatitisb1.shtml
- Christopher S, William SM. Heptatis B virus Biology. Microbiology and Molecular Biology Reviews. 2000;64(1):51–68. doi: 10.1128/MMBR.64.1.51-68.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cohen Sidney. Acute viral hepatitis. The Merck manual online Medical Library. 2007. © 2006-2008.
- Gitlin Norman. Hepatitis B: diagnosis, Prevention and Treatment. Clinical Chemistry. 1997;43:8(B):1500–1506. [PubMed] [Google Scholar]
- Kumar H, Gupta PK, Jaiprakash Brig M. The role of anti-HBc IgM in Screening of Blood Donors. MJAFI. 2007;63:350–352. doi: 10.1016/S0377-1237(07)80013-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Geraldine K, Adel A, Intesar A, Jameel N, Said HA. Evidence of occult Hepatitis B Virus infection among Omani Blood Donors: A preliminary study. Medical Principle and Practice. pp. 368–372. [DOI] [PubMed]
- Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, Kudo M, Yamamoto Y, Kojima H, Seno H, Moriyasu F, Chiba T. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis c virus related chronic liver disease in Japan. Gut. 1999;45(2):284–288. doi: 10.1136/gut.45.2.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Panhotra BR, Bahrani A, Joshi CS, Ul Hassan Zahoor. Occult hepatitis B virus infection among anti HBc positive blood donors: Necessitates substitutionof screening by HBV NAT. J Infect. 2005;51(3):263. doi: 10.1016/j.jinf.2005.07.023. [DOI] [PubMed] [Google Scholar]
- Hennig H, Puchta I, Luhm J, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood. 2002;100:2637–41. doi: 10.1182/blood-2002-03-0798. [DOI] [PubMed] [Google Scholar]
- Muhlbacher A, Zdunek D, Melchior W, Michl U. Is infective blood donation missed out without screening for antibody to hepatitis B core antigen and/or hepatitis B virus DNA. Vox Sang. 2001;81:139. doi: 10.1046/j.1423-0410.2001.00086.x. [DOI] [PubMed] [Google Scholar]
- Vyas GN. In: Transfusion associated hepatitis. Diagnosis, treatment and prevention. Sarin SK, Hess G, eds, editor. New Delhi: CBS Publishers & Distributors; 1998. Significance of HBV DNA in HBsAg negative individuals: a critical commentary; pp. 49–56. [Google Scholar]
- Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic screening for blood donors in India reveals a lack of correlation between anti-HBC titre and PCR amplified HBV DNA. Transfusion. 2006;43(10):1442–1448. doi: 10.1046/j.1537-2995.2003.00512.x. [DOI] [PubMed] [Google Scholar]
- Hoofnagle JH, Seef LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298:1379–83. doi: 10.1056/NEJM197806222982502. [DOI] [PubMed] [Google Scholar]
- Douglas DD, Taswell HF, Rakela J, Rabe D. Absence of hepatitis B DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers. Transfusion. 1993;33:212–6. doi: 10.1046/j.1537-2995.1993.33393174446.x. [DOI] [PubMed] [Google Scholar]
- Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, Werch J, Edwards V. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of Transfusion Transmitted Virus Study. Ann Intern Med. 1984;101:733–8. doi: 10.7326/0003-4819-101-6-733. [DOI] [PubMed] [Google Scholar]
- Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, Barbosa LH, Nemo GJ. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion. 1995;35:5–12. doi: 10.1046/j.1537-2995.1995.35195090661.x. [DOI] [PubMed] [Google Scholar]
- Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Gunther S, Hess G, Hudig H, Kitchen A, Margolis H, Michel G, Trepo C, Will H, Zanetti A, Mushahwar I. Serological pattern 'anti-HBc alone': Report on a workshop. J Med Virol. 2000;62:450–5. doi: 10.1002/1096-9071(200012)62:4<450::AID-JMV9>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
- Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83–91. doi: 10.1111/j.0042-9007.2004.00406.x. [DOI] [PubMed] [Google Scholar]
- Ojo OS, Thursz M, Thomas HC, Ndububa DA, Adeodu oo, Rotimi O, Lawal AA, Durosimi MA, Akonai AK, Fatusi AO, Goldn RD. Hepatitis B virus markers, hepatitis D virus antigen and hepatitis C virus antibodies in Nigerian patients with chronic liver disease. East Afr Med J. 1995;72(11):719–21. [PubMed] [Google Scholar]
- Neirmeijer P, Gips CH. Viral antibodies and the infectivity of serum in hepatitis B. N Engl J Med. 1978;299:958. doi: 10.1056/NEJM197810262991721. [DOI] [PubMed] [Google Scholar]
- van Ditzhuijsen TJ, Selten GC, van Loon AM, Wolters G, Matthyssen L, Yap SH. Detection of hepatitis B DNA in serum and relation with the IgM class anti-HBc titres in hepatitis B infection. J Med Virol. 1985;15:49–56. doi: 10.1002/jmv.1890150107. [DOI] [PubMed] [Google Scholar]
- Sawke Nilima G, Sawke GK. Preventing Post-Transfusion Hepatitis by screening blood donors for IgM Antibody to Hepatitis B core antigen. J Glob Infect Dis. 2010;2(3):246–247. doi: 10.4103/0974-777X.68526. [DOI] [PMC free article] [PubMed] [Google Scholar]